The United States is the global leader in biopharmaceutical research and development. This position is crucial to the economy and giving patients access to new medicines well before they are available in foreign countries. Unfortunately, steps are being taken to put this leadership at risk and push research and development overseas. On October 22, 2026, […]
Tobacco harm reduction (THR) products have been proven to be an effective and accessible way for smokers to quit smoking cigarettes. However, it takes years for the Food and Drug Administration (FDA) to approve these products so that they can reach or remain on the market. A September 30, 2026, Government Accountability Office (GAO) report […]
The 340B Drug Discount program was created in 1992 to help federally funded clinics and public hospitals that serve a large uninsured population cover the cost of drugs and provide discounts to patients. However, because Congress never defined an eligible patient and neglected programmatic accountability and transparency, the program has enabled hospitals and contract pharmacies […]
Tobacco harm reduction (THR) products have proven to be an effective and accessible way for smokers to quit cigarettes. E-cigarettes are perhaps the most popular THR product, but clinicians are often hesitant to recommend them to patients. A July 30, 2026, Journal of the American Medical Association (JAMA) article should lead to wider acceptance and […]
The transmission of critical medical information is stuck in the past. Due to an outdated and unnecessary rule, pharmacies and healthcare providers still receive prescription drug information on paper, which is wasteful, harmful to the environment, and nonsensical. Legislation to update this process and bring common sense to the dissemination of this critical information has […]
Price controls in any industry do not work and inevitably lead to shortages and disrupted markets. Price controls on biopharmaceuticals are especially harmful because they raise costs, stifle research and development of new cures and treatments, and threaten America’s position as the global industry leader. As the Inflation Reduction Act (IRA) was being considered by […]
The 340B Drug Discount Program started in 1992 with the laudable intention of helping federally funded hospitals that serve a large number of uninsured patients cover the costs of drugs and provide discounts to patients. However, due to the lack of a clear definition of an eligible patient and poor oversight, the program has drifted […]
Eliminating waste, fraud, and abuse continues to be a priority across the legislative and executive branches of the federal government. Lawmakers who are fighting against wasteful spending should agree to eliminate an outdated and unnecessary rule that would result in the modernization of how critical medical information is transmitted. It would both bring common sense […]
Tobacco harm reduction (THR) products have been proven to be a safer alternative to cigarettes and an effective way to help smokers quit. On June 30, 2026, the Food and Drug Administration (FDA) took a significant step to increase the availability and use of THR products by announcing the approval of 20 Zyn nicotine pouch […]
The U.S. is the global leader in pharmaceutical research and development, and foreign countries have been taking advantage of this investment by not paying their fair share of those costs. On June 18, 2026, the Trump administration took a step in the right direction to resolve this problem when the United States Trade Representative (USTR) […]
